Arcus Biosciences, Inc. (RCUS) Financials
RCUS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.1 billion | 633.0 million |
2023-09-30 | 1.2 billion | 671.0 million |
2023-06-30 | 1.2 billion | 654.0 million |
2023-03-31 | 1.3 billion | 654.0 million |
RCUS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -94.0 million | 18.0 million |
2023-09-30 | -73.0 million | 18.0 million |
2023-06-30 | -62.0 million | 18.0 million |
2023-03-31 | -101.0 million | 19.0 million |
RCUS Net Income
No data available :(
RCUS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 759.0 million | - | 11.0 million |
2023-09-30 | 950.0 million | - | 9.0 million |
2023-06-30 | 1.0 billion | - | - |
2023-03-31 | 1.0 billion | - | - |
RCUS Shares Outstanding
RCUS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 6.0 million | 93.0 million | 29.0 million | - |
2023-09-30 | 10.0 million | 82.0 million | 30.0 million | - |
2023-06-30 | 5.0 million | 84.0 million | 28.0 million | - |
2023-03-31 | 3.0 million | 81.0 million | 30.0 million | - |
RCUS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 31.0 million | 5.0 million |
2023-09-30 | 32.0 million | 3.0 million |
2023-06-30 | 29.0 million | 4.0 million |
2023-03-31 | 25.0 million | 4.0 million |
RCUS
Price: $15.23
52 week price:
Earnings Per Share: -4.15 USD
P/E Ratio: -3.83
Exchange: NYQ
Sector: Healthcare
Industry: Biotechnology
Volume: 965900
Market Capitalization: 1.6 billion